Cargando…
Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study
BACKGROUND: Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal. The role of HBV prophylaxis in this setting is uncertain. The aim of this study was to compare the efficacy of tenofovir disoproxil fumarate...
Autores principales: | Buti, María, Manzano, María L., Morillas, Rosa M., García-Retortillo, Montserrat, Martín, Leticia, Prieto, Martín, Gutiérrez, María L., Suárez, Emilio, Gómez Rubio, Mariano, López, Javier, Castillo, Pilar, Rodríguez, Manuel, Zozaya, José M., Simón, Miguel A., Morano, Luis E., Calleja, José L., Yébenes, María, Esteban, Rafael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595327/ https://www.ncbi.nlm.nih.gov/pubmed/28898281 http://dx.doi.org/10.1371/journal.pone.0184550 |
Ejemplares similares
-
Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study
por: Buti, María, et al.
Publicado: (2018) -
Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B
por: Mateos-Muñoz, Beatriz, et al.
Publicado: (2023) -
Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021) -
Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
por: Cui, Guangying, et al.
Publicado: (2015) -
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023)